SG11201702041PA - Cot modulators and methods of use thereof - Google Patents
Cot modulators and methods of use thereofInfo
- Publication number
- SG11201702041PA SG11201702041PA SG11201702041PA SG11201702041PA SG11201702041PA SG 11201702041P A SG11201702041P A SG 11201702041PA SG 11201702041P A SG11201702041P A SG 11201702041PA SG 11201702041P A SG11201702041P A SG 11201702041PA SG 11201702041P A SG11201702041P A SG 11201702041PA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- cot
- modulators
- cot modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562189158P | 2015-07-06 | 2015-07-06 | |
US201562269060P | 2015-12-17 | 2015-12-17 | |
PCT/US2016/040520 WO2017007689A1 (en) | 2015-07-06 | 2016-06-30 | Cot modulators and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201702041PA true SG11201702041PA (en) | 2017-04-27 |
Family
ID=56411943
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201702041PA SG11201702041PA (en) | 2015-07-06 | 2016-06-30 | Cot modulators and methods of use thereof |
Country Status (40)
Country | Link |
---|---|
US (6) | US20170008905A1 (es) |
EP (3) | EP3896064A1 (es) |
JP (5) | JP6430060B2 (es) |
KR (5) | KR101974793B1 (es) |
CN (3) | CN114380799A (es) |
AU (4) | AU2016290820B2 (es) |
BR (1) | BR102016015656B1 (es) |
CA (1) | CA2971640C (es) |
CL (1) | CL2017003356A1 (es) |
CO (1) | CO2017013351A2 (es) |
CR (1) | CR20170599A (es) |
CU (1) | CU20170172A7 (es) |
CY (1) | CY1121750T1 (es) |
DK (1) | DK3191470T3 (es) |
DO (1) | DOP2017000311A (es) |
EA (1) | EA036788B1 (es) |
EC (1) | ECSP17084635A (es) |
ES (2) | ES2872076T3 (es) |
HR (1) | HRP20190853T1 (es) |
HU (1) | HUE043310T2 (es) |
IL (4) | IL274568B (es) |
LT (1) | LT3191470T (es) |
MA (1) | MA39422B1 (es) |
ME (1) | ME03425B (es) |
MX (1) | MX370984B (es) |
MY (1) | MY196173A (es) |
NZ (2) | NZ738525A (es) |
PE (1) | PE20180462A1 (es) |
PH (2) | PH12018500031A1 (es) |
PL (2) | PL3456717T3 (es) |
PT (2) | PT3456717T (es) |
RS (1) | RS58639B1 (es) |
SA (1) | SA517381350B1 (es) |
SG (1) | SG11201702041PA (es) |
SI (2) | SI3191470T1 (es) |
SV (1) | SV2017005605A (es) |
TW (3) | TWI699361B (es) |
UA (1) | UA123010C2 (es) |
UY (1) | UY36771A (es) |
WO (1) | WO2017007689A1 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6205354B2 (ja) | 2011-07-06 | 2017-09-27 | ギリアード サイエンシーズ, インコーポレイテッド | Hivの処置のための化合物 |
US10118890B2 (en) | 2014-10-10 | 2018-11-06 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
EP3319955B1 (en) | 2015-07-06 | 2020-11-25 | Gilead Sciences, Inc. | 6-amino-quinoline-3-carbonitrils as cot modulators |
IL274568B (en) | 2015-07-06 | 2022-07-01 | Gilead Sciences Inc | Modulators of cot and methods of using them |
EP3478674B1 (en) | 2016-06-30 | 2020-05-13 | Gilead Sciences, Inc. | 4,6-diaminoquinazolines as cot modulators and methods of use thereof |
KR102180740B1 (ko) * | 2016-08-19 | 2020-11-20 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 바이러스 감염의 예방적 또는 치유적 치료에 유용한 치료 화합물 |
EA036921B1 (ru) * | 2017-02-10 | 2021-01-15 | Джилид Сайэнс, Инк. | Терапевтические соединения, которые можно применять для профилактического или терапевтического лечения инфекции вирусом вич |
CN108794516A (zh) * | 2017-04-26 | 2018-11-13 | 上海时莱生物技术有限公司 | 硼酸和硼酸酯类化合物及其制备方法和用途 |
AR112413A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas sólidas de un inhibidor de la cápside del vih |
AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
EP3689866A4 (en) * | 2017-09-26 | 2021-07-07 | Nippon Soda Co., Ltd. | QUINOLINE COMPOUND AND BACTERICIDAL AGENT FOR AGRICULTURE AND HORTICULTURE |
CA3089590C (en) | 2018-02-15 | 2022-12-06 | Gilead Sciences, Inc. | Pyridine derivatives and their use for treating hiv infection |
AR114631A1 (es) | 2018-02-16 | 2020-09-30 | Gilead Sciences Inc | Métodos e intermedios para preparar compuestos de piridina |
WO2019168874A1 (en) | 2018-02-27 | 2019-09-06 | The Research Foundation For The State University Of New York | Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same |
CN110294660B (zh) * | 2018-03-23 | 2021-09-24 | 中国农业大学 | 一种含碳碳三键和/或碳氮三键的不饱和有机化合物的还原氘化方法 |
CN108658996A (zh) * | 2018-06-25 | 2018-10-16 | 中国药科大学 | 一种氘代Fiduxosin的制备方法 |
KR20210033492A (ko) | 2018-07-16 | 2021-03-26 | 길리애드 사이언시즈, 인코포레이티드 | Hiv의 치료를 위한 캡시드 억제제 |
TW202235416A (zh) | 2019-06-14 | 2022-09-16 | 美商基利科學股份有限公司 | Cot 調節劑及其使用方法 |
CN114585619A (zh) | 2019-08-29 | 2022-06-03 | 爱杜西亚药品有限公司 | α-D-吡喃半乳糖苷衍生物 |
JP2023502530A (ja) | 2019-11-26 | 2023-01-24 | ギリアード サイエンシーズ, インコーポレイテッド | Hiv予防のためのカプシド阻害剤 |
JP2023520650A (ja) * | 2020-03-30 | 2023-05-18 | ギリアード サイエンシーズ, インコーポレイテッド | (S)-6-(((1-(ビシクロ[1.1.1]ペンタン-1-イル)-1H-1,2,3-トリアゾール-4-イル)2-メチル-1-オキソ-1,2-ジヒドロイソキノリン-5-イル)メチル)))アミノ)8-クロロ-(ネオペンチルアミノ)キノリン-3-カルボニトリルCot阻害剤化合物の固体形態 |
AU2021245924B2 (en) * | 2020-04-02 | 2024-02-29 | Gilead Sciences, Inc. | Process for preparing a Cot inhibitor compound |
WO2021262990A1 (en) | 2020-06-25 | 2021-12-30 | Gilead Sciences, Inc. | Capsid inhibitors for the treatment of hiv |
EP4301748A1 (en) | 2021-03-03 | 2024-01-10 | Idorsia Pharmaceuticals Ltd | Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives |
TW202304435A (zh) * | 2021-06-04 | 2023-02-01 | 美商基利科學股份有限公司 | 治療nash之方法 |
IL308228A (en) * | 2021-06-11 | 2024-01-01 | Neuronascent Inc | Methods and preparations for lipid formulation of lipophilic treatments small molecules of the heterocyclic type |
US11787825B2 (en) | 2021-12-03 | 2023-10-17 | Gilead Sciences, Inc. | Therapeutic compounds for HIV virus infection |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3930837A (en) | 1971-12-31 | 1976-01-06 | Ici Australia Limited | 3-chloro-5-acetamidaisoquinoline as a herbicide |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US4151298A (en) | 1977-01-10 | 1979-04-24 | Ciba-Geigy Corporation | Anthelmintic compositions |
US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
JP2634438B2 (ja) | 1988-07-26 | 1997-07-23 | 三井東圧化学株式会社 | 不斉ビスオキサゾリルピリジン誘導体およびその製造方法 |
DE4014171A1 (de) | 1990-05-03 | 1991-11-07 | Basf Ag | Cyanochinolinverbindungen |
GB9310700D0 (en) | 1993-05-24 | 1993-07-07 | Zeneca Ltd | Novel composition |
UA73073C2 (uk) * | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
AU734678B2 (en) | 1997-08-28 | 2001-06-21 | Nissan Chemical Industries Ltd. | Industrial antibacterial and antifungal agents, algicides and agents for preventing adhesion of organisms containing a cyanoacrylate compound |
ATE316532T1 (de) | 1998-07-10 | 2006-02-15 | Massachusetts Inst Technology | Liganden für metalle und metall-katalysiertes verfahren |
BR9914164A (pt) * | 1998-09-29 | 2001-06-26 | American Cyanamid Co | Composto, método para o tratamento, inibição do crescimento de, ou erradiacação de um neoplasma, e de doença de rim policìstico, em um mamìfero em necessidade do mesmo, composição farmacêutica, e, processo para preparar um composto |
EP1485085A4 (en) | 2002-03-20 | 2007-03-14 | Bristol Myers Squibb Co | PHOSPHATE PRODRUGS OF FLUORO XINDOLS |
CN100395237C (zh) | 2003-03-03 | 2008-06-18 | 弗·哈夫曼-拉罗切有限公司 | 用作5-ht6调节剂的2,5-取代的四氢异喹啉 |
MXPA06001590A (es) | 2003-08-19 | 2006-05-19 | Wyeth Corp | Proceso para la preparacion de 4-amino-3-quinolincarbonitrilos. |
US7399865B2 (en) * | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
TW200529846A (en) * | 2004-02-20 | 2005-09-16 | Wyeth Corp | 3-quinolinecarbonitrile protein kinase inhibitors |
GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
JP2008540667A (ja) * | 2005-05-18 | 2008-11-20 | ワイス | Tpl2キナーゼの4,6−ジアミノ−[1,7]ナフチリジン−3−カルボニトリル阻害物質ならびにそれを製造および使用する方法 |
CA2608540A1 (en) | 2005-05-18 | 2006-11-23 | Wyeth | 3-cyanoquinoline inhibitors of tpl2 kinase and methods of making and using the same |
BRPI0617884A2 (pt) | 2005-10-28 | 2011-08-09 | Abbott Lab | derivados de indazol que inibem receptor trpv1 |
JP5255559B2 (ja) | 2006-03-31 | 2013-08-07 | アボット・ラボラトリーズ | インダゾール化合物 |
EP2086960B1 (en) | 2006-11-09 | 2014-03-05 | Probiodrug AG | Novel inhibitors of glutaminyl cyclase |
WO2008092292A1 (en) | 2007-01-17 | 2008-08-07 | The Hong Kong University Of Science And Technology | Isoquinolone compounds as subtype-selective agonists for melatonin receptors mt1 and mt2 |
GB0820856D0 (en) | 2008-11-14 | 2008-12-24 | Univ Leuven Kath | Novel inhibitors of flavivirus replication |
TWI598347B (zh) | 2009-07-13 | 2017-09-11 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
GB0922302D0 (en) * | 2009-12-22 | 2010-02-03 | Imp Innovations Ltd | Compounds |
CN103038364A (zh) | 2010-03-09 | 2013-04-10 | 达纳-法伯癌症研究所公司 | 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法 |
WO2011153942A1 (zh) * | 2010-06-09 | 2011-12-15 | 天津和美生物技术有限公司 | 氰基喹啉衍生物 |
WO2012153796A1 (ja) | 2011-05-10 | 2012-11-15 | 協和発酵キリン株式会社 | ピリミドジアゼピノン化合物 |
EP2729007A1 (de) | 2011-07-04 | 2014-05-14 | Bayer Intellectual Property GmbH | Verwendung substituierter isochinolinone, isochinolindione, isochinolintrione und dihydroisochinolinone oder jeweils deren salze als wirkstoffe gegen abiotischen pflanzenstress |
EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
MY168930A (en) | 2011-10-27 | 2019-01-09 | Taisho Pharmaceutical Co Ltd | Azole derivative |
PL2776038T3 (pl) | 2011-11-11 | 2018-06-29 | Gilead Apollo, Llc | Inhibitory acc i ich zastosowania |
UY34573A (es) | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | Inhibidor de la quinasa que regula la señal de la apoptosis |
CN103483363B (zh) | 2012-06-13 | 2016-12-21 | 上海赛迦化工产品有限公司 | 多样性的手性氨基硼酸及其制备方法和应用 |
IN2015DN03795A (es) | 2012-10-24 | 2015-10-02 | Inserm Inst Nat De La Santé Et De La Rech Médicale | |
CN103408572B (zh) | 2013-07-12 | 2015-12-02 | 上海工程技术大学 | 手性氨基硼酸衍生物及其制备方法和应用 |
US10189780B2 (en) | 2013-12-12 | 2019-01-29 | Zeno Royalties & Milestones, LLC | Bicyclic alkyl compounds and synthesis |
CN106232567B (zh) | 2014-03-07 | 2021-11-02 | 里科瑞尔姆Ip控股有限责任公司 | 螺桨烷衍生物及合成 |
US9701661B2 (en) * | 2014-07-11 | 2017-07-11 | Northwestern University | 2-imidazolyl-pyrimidine scaffolds as potent and selective inhibitors of neuronal nitric oxide synthase |
EP3193855B1 (en) | 2014-09-17 | 2021-05-19 | Recurium IP Holdings, LLC | Bicyclic compounds |
NZ729678A (en) | 2014-09-24 | 2018-07-27 | Gilead Sciences Inc | Methods of treating non-alcoholic steatohepatitis using ask1 inhibitor in combination with a fxr agonist |
CA3202893A1 (en) | 2014-12-23 | 2016-06-30 | Gilead Science, Inc. | Processes for preparing ask1 inhibitors |
MA41252A (fr) | 2014-12-23 | 2017-10-31 | Gilead Sciences Inc | Formes solides d'un inhibiteur d'ask 1 |
CA2972919A1 (en) | 2015-01-09 | 2016-07-14 | Gilead Apollo, Llc | Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease |
KR102205143B1 (ko) | 2015-01-16 | 2021-01-21 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | 그리드 결과를 개선하기 위해 그리드 액션을 선택하기 위한 시스템 및 방법 |
EP3319955B1 (en) * | 2015-07-06 | 2020-11-25 | Gilead Sciences, Inc. | 6-amino-quinoline-3-carbonitrils as cot modulators |
IL274568B (en) | 2015-07-06 | 2022-07-01 | Gilead Sciences Inc | Modulators of cot and methods of using them |
DK3398598T3 (da) | 2015-12-31 | 2022-07-11 | Hitgen Inc | Sulfonamidderivat og fremstillingsmetode og anvendelse deraf |
TW202400605A (zh) | 2016-03-02 | 2024-01-01 | 美商基利阿波羅有限責任公司 | 噻吩并嘧啶二酮acc抑制劑之固體型式及其製造方法 |
JP6738895B2 (ja) | 2016-06-21 | 2020-08-12 | Phcホールディングス株式会社 | カタラーゼ阻害剤及びカタラーゼ阻害剤を用いるアナライトの測定方法 |
EP3478674B1 (en) | 2016-06-30 | 2020-05-13 | Gilead Sciences, Inc. | 4,6-diaminoquinazolines as cot modulators and methods of use thereof |
CN106512014A (zh) | 2016-10-27 | 2017-03-22 | 武汉大学 | 肿瘤进展位点2在治疗脂肪肝和ⅱ型糖尿病中的功能和应用 |
EP4273132A3 (en) | 2017-03-03 | 2024-01-10 | Gilead Sciences, Inc. | Processes for preparing acc inhibitors and solid forms thereof |
AU2018243719B2 (en) | 2017-03-28 | 2021-01-21 | Gilead Sciences, Inc. | Therapeutic combinations for treating liver diseases |
JP2020516627A (ja) | 2017-04-12 | 2020-06-11 | ギリアード サイエンシーズ, インコーポレイテッド | 肝疾患を処置する方法 |
US10980810B2 (en) | 2017-10-06 | 2021-04-20 | Gilead Sciences, Inc. | Combination therapy comprising an ACC inhibitor |
CA3233305A1 (en) | 2019-02-19 | 2020-08-27 | Gilead Sciences, Inc. | Solid forms of fxr agonists |
EP3934615A4 (en) | 2019-03-08 | 2023-01-25 | The Regents Of The University Of California | COMPOSITIONS AND METHODS FOR TREATMENT OF ACNE |
TW202235416A (zh) | 2019-06-14 | 2022-09-16 | 美商基利科學股份有限公司 | Cot 調節劑及其使用方法 |
AR119594A1 (es) | 2019-08-09 | 2021-12-29 | Gilead Sciences Inc | Derivados de tienopirimidina como inhibidores acc y usos de los mismos |
JP2023520650A (ja) | 2020-03-30 | 2023-05-18 | ギリアード サイエンシーズ, インコーポレイテッド | (S)-6-(((1-(ビシクロ[1.1.1]ペンタン-1-イル)-1H-1,2,3-トリアゾール-4-イル)2-メチル-1-オキソ-1,2-ジヒドロイソキノリン-5-イル)メチル)))アミノ)8-クロロ-(ネオペンチルアミノ)キノリン-3-カルボニトリルCot阻害剤化合物の固体形態 |
AU2021245924B2 (en) | 2020-04-02 | 2024-02-29 | Gilead Sciences, Inc. | Process for preparing a Cot inhibitor compound |
TW202304435A (zh) | 2021-06-04 | 2023-02-01 | 美商基利科學股份有限公司 | 治療nash之方法 |
-
2016
- 2016-06-30 IL IL274568A patent/IL274568B/en unknown
- 2016-06-30 US US15/199,534 patent/US20170008905A1/en not_active Abandoned
- 2016-06-30 NZ NZ738525A patent/NZ738525A/en unknown
- 2016-06-30 PE PE2017002804A patent/PE20180462A1/es unknown
- 2016-06-30 MY MYPI2018700007A patent/MY196173A/en unknown
- 2016-06-30 CN CN202210008753.1A patent/CN114380799A/zh active Pending
- 2016-06-30 KR KR1020187003221A patent/KR101974793B1/ko active IP Right Grant
- 2016-06-30 EA EA201792613A patent/EA036788B1/ru unknown
- 2016-06-30 PL PL18186568T patent/PL3456717T3/pl unknown
- 2016-06-30 KR KR1020227031078A patent/KR20220129667A/ko not_active Application Discontinuation
- 2016-06-30 UA UAA201712984A patent/UA123010C2/uk unknown
- 2016-06-30 MX MX2017004737A patent/MX370984B/es active IP Right Grant
- 2016-06-30 CN CN201910292757.5A patent/CN109879859B/zh active Active
- 2016-06-30 SG SG11201702041PA patent/SG11201702041PA/en unknown
- 2016-06-30 KR KR1020247000058A patent/KR20240008398A/ko not_active Application Discontinuation
- 2016-06-30 CN CN201680050602.5A patent/CN107922390B/zh active Active
- 2016-06-30 ES ES18186568T patent/ES2872076T3/es active Active
- 2016-06-30 WO PCT/US2016/040520 patent/WO2017007689A1/en active Application Filing
- 2016-06-30 ES ES16738976T patent/ES2734713T3/es active Active
- 2016-06-30 SI SI201630202T patent/SI3191470T1/sl unknown
- 2016-06-30 MA MA39422A patent/MA39422B1/fr unknown
- 2016-06-30 KR KR1020197011792A patent/KR102073641B1/ko active IP Right Grant
- 2016-06-30 CR CR20170599A patent/CR20170599A/es unknown
- 2016-06-30 IL IL293770A patent/IL293770B2/en unknown
- 2016-06-30 HU HUE16738976A patent/HUE043310T2/hu unknown
- 2016-06-30 EP EP21162393.9A patent/EP3896064A1/en active Pending
- 2016-06-30 RS RS20190498A patent/RS58639B1/sr unknown
- 2016-06-30 PT PT181865684T patent/PT3456717T/pt unknown
- 2016-06-30 JP JP2018500585A patent/JP6430060B2/ja active Active
- 2016-06-30 LT LTEP16738976.6T patent/LT3191470T/lt unknown
- 2016-06-30 AU AU2016290820A patent/AU2016290820B2/en active Active
- 2016-06-30 EP EP16738976.6A patent/EP3191470B1/en active Active
- 2016-06-30 KR KR1020207002878A patent/KR102443575B1/ko active IP Right Grant
- 2016-06-30 ME MEP-2019-117A patent/ME03425B/me unknown
- 2016-06-30 CA CA2971640A patent/CA2971640C/en active Active
- 2016-06-30 SI SI201631197T patent/SI3456717T1/sl unknown
- 2016-06-30 EP EP18186568.4A patent/EP3456717B1/en active Active
- 2016-06-30 PL PL16738976T patent/PL3191470T3/pl unknown
- 2016-06-30 PT PT16738976T patent/PT3191470T/pt unknown
- 2016-06-30 NZ NZ750707A patent/NZ750707A/en unknown
- 2016-06-30 CU CUP2017000172A patent/CU20170172A7/es unknown
- 2016-06-30 DK DK16738976.6T patent/DK3191470T3/en active
- 2016-07-04 BR BR102016015656-4A patent/BR102016015656B1/pt active IP Right Grant
- 2016-07-05 TW TW107117905A patent/TWI699361B/zh active
- 2016-07-05 TW TW105121281A patent/TWI634112B/zh active
- 2016-07-05 TW TW109122003A patent/TWI748539B/zh active
- 2016-07-06 UY UY0001036771A patent/UY36771A/es not_active Application Discontinuation
-
2017
- 2017-02-09 US US15/429,086 patent/US9878995B2/en active Active
- 2017-04-18 SA SA517381350A patent/SA517381350B1/ar unknown
- 2017-12-20 IL IL256433A patent/IL256433B/en active IP Right Grant
- 2017-12-22 EC ECIEPI201784635A patent/ECSP17084635A/es unknown
- 2017-12-22 SV SV2017005605A patent/SV2017005605A/es unknown
- 2017-12-22 CO CONC2017/0013351A patent/CO2017013351A2/es unknown
- 2017-12-22 CL CL2017003356A patent/CL2017003356A1/es unknown
- 2017-12-26 DO DO2017000311A patent/DOP2017000311A/es unknown
-
2018
- 2018-01-03 PH PH12018500031A patent/PH12018500031A1/en unknown
- 2018-02-07 US US15/891,163 patent/US20180237455A1/en not_active Abandoned
- 2018-09-13 JP JP2018171794A patent/JP6781221B2/ja active Active
-
2019
- 2019-04-23 US US16/391,673 patent/US20190248807A1/en not_active Abandoned
- 2019-05-03 AU AU2019203122A patent/AU2019203122B2/en active Active
- 2019-05-08 HR HRP20190853TT patent/HRP20190853T1/hr unknown
- 2019-05-20 CY CY20191100535T patent/CY1121750T1/el unknown
- 2019-05-29 IL IL266995A patent/IL266995B/en active IP Right Grant
- 2019-07-26 JP JP2019137759A patent/JP6906021B2/ja active Active
- 2019-12-17 US US16/717,074 patent/US11066414B2/en active Active
-
2020
- 2020-09-06 PH PH12020551397A patent/PH12020551397A1/en unknown
- 2020-10-20 AU AU2020257055A patent/AU2020257055B2/en active Active
- 2020-12-16 JP JP2020208330A patent/JP7138155B2/ja active Active
-
2021
- 2021-05-11 US US17/317,041 patent/US11905299B2/en active Active
-
2022
- 2022-04-11 JP JP2022065168A patent/JP2022082816A/ja active Pending
- 2022-06-10 AU AU2022204050A patent/AU2022204050B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL274568A (en) | COT modulators and methods of using them | |
IL286316A (en) | New micro-dystrophins and related method of use | |
IL290571A (en) | Molecules that bind pd-1 and methods of using them | |
HK1252827A1 (zh) | 結合lag-3的分子和其使用方法 | |
IL250415B (en) | Antibodies against pd-l and methods of using them | |
PT3310801T (pt) | Moduladores de tgr5 e métodos de utilização dos mesmos | |
HK1251486A1 (zh) | Sestrin-gator2相互作用的調節劑和其用途 | |
IL282482A (en) | Variants of protoxin-II and methods of use | |
HK1252567A1 (zh) | 被取代的苯甲酰胺和其使用方法 | |
IL282508A (en) | Variants of protoxin-II and methods of use | |
HK1251579A1 (zh) | Tgr5調節劑及其使用方法 |